Moderna to acquire oriciro genomics

Oriciro's synthetic biology and enzyme technologies will support moderna's expanding portfolio of therapeutics and vaccines acquisition will bolster moderna's suite of platform technologies cambridge, ma and tokyo, japan / accesswire / january 4, 2023 / moderna, inc. (nasdaq:mrna), a biotechnology company pioneering messenger rna (mrna) therapeutics and vaccines, and oriciro genomics k.k., a pioneer in cell-free dna synthesis and amplification technologies, today announced they have entered into a definitive agreement through which moderna will acquire oriciro for $85 million.
MRNA Ratings Summary
MRNA Quant Ranking